Tilray Brands (TLRY) Consolidated Net Income (2017 - 2026)
Tilray Brands (TLRY) reported Consolidated Net Income of -$25.2 million for Q1 2026, up 96.82% on a YoY basis from -$12.8 million in Q1 2025, and up 42.01% quarter-over-quarter from -$43.5 million in Q4 2025.
Tilray Brands (TLRY) Consolidated Net Income (2017 - 2026) Analysis & Trends
Tilray Brands has reported Consolidated Net Income for 10 years, with the latest figure at -$25.2 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income rose 96.82% year-over-year to -$25.2 million; the trailing twelve-month figure through Feb 2026 stood at -$680.9 million (up 29.63% YoY), and the FY2025 full-year result was -$1.5 billion, down 484.5% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$25.2 million, up from -$43.5 million in the prior quarter.
- The five-year high for Consolidated Net Income was $52.5 million in Q1 2022, with the low at -$1.2 billion in Q1 2023.
- Historically, Consolidated Net Income has averaged -$219.3 million across 5 years, with a median of -$65.8 million in 2022.
- The largest YoY upside for Consolidated Net Income was 120.29% in 2022 against a maximum downside of 5346.39% in 2022.
- Tilray Brands' Consolidated Net Income stood at -$85.1 million in 2022, then jumped by 45.71% to -$46.2 million in 2023, then sank by 84.65% to -$85.3 million in 2024, then jumped by 48.98% to -$43.5 million in 2025, then soared by 42.01% to -$25.2 million in 2026.
- The last three Consolidated Net Income figures came in at -$25.2 million (Q1 2026), -$43.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -114,733.81 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Tilray Brands | - | - | 54.95 Mn | -25.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -25.23 Mn |
| Nov 30, 2025 | -43.51 Mn |
| Aug 31, 2025 | 1.51 Mn |
| May 31, 2025 | -613.71 Mn |
| Feb 28, 2025 | -793.53 Mn |
| Nov 30, 2024 | -85.28 Mn |
| Aug 31, 2024 | -34.65 Mn |
| May 31, 2024 | -54.25 Mn |
| Feb 29, 2024 | -104.98 Mn |
| Nov 30, 2023 | -46.18 Mn |
| Aug 31, 2023 | -55.86 Mn |
| May 31, 2023 | -119.82 Mn |
| Feb 28, 2023 | -1.20 Bn |
| Nov 30, 2022 | -85.06 Mn |
| Aug 31, 2022 | -65.79 Mn |
| May 31, 2022 | -457.80 Mn |
| Feb 28, 2022 | 52.48 Mn |
| Nov 30, 2021 | 5.80 Mn |
| Aug 31, 2021 | -34.60 Mn |
| May 31, 2021 | 8.73 Mn |